Evidence map›Paper›PMID 27829290›Full record

ArticleInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2017

HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.

Arin N Graner, Justin E Hellwinkel, Alex M Lencioni, Helen J Madsen, Tessa A Harland, Paul Marchando, Ger J Nguyen, Mary Wang, Laura M Russell, Lynne T Bemis and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Arin N Granera Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
Justin E Hellwinkela Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
Alex M Lencionia Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
Helen J Madsena Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
Tessa A Harlanda Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
Paul Marchandod Department of Chemical and Biological Engineering , University of Colorado Boulder , Boulder , CO , USA.
Ger J Nguyena Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
Mary Wanga Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
Laura M Russella Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
Lynne T Bemise Department of Biomedical Sciences , University of Minnesota , Duluth , MN , USA.
Thomas J Anchordoquyf Skaggs School of Pharmacy and Pharmaceutical Sciences , University of Colorado Denver , Aurora , CO , USA.
Michael W Granera Department of Neurosurgery , University of Colorado Denver , Aurora , CO , USA.
University of Colorado Denver · USUniversity of Arkansas for Medical Sciences · USUniversity of Colorado Boulder · USUniversity of Minnesota, Duluth · USUniversity of Montana · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Tumor-Homing Exosomes for Drug DeliveryR01EB016378 · NIBIB · UNIVERSITY OF COLORADO DENVER · PI ANCHORDOQUY, THOMAS, GRANER, MICHAEL W. · 2013 to 2016
$1.5M
NCI NIH HHS P30 CA046934NIBIB NIH HHS R01 EB016378
6 · The paper itself

Abstract

backgroundAgents targeting HSP90 and GRP94 are seldom tested in stressed contexts such as heat shock (HS) or the unfolded protein response (UPR). Tumor stress often activates HSPs and the UPR as pro-survival mechanisms. This begs the question of stress effects on chemotherapeutic efficacy, particularly with drugs targeting chaperones such as HSP90 or GRP94. We tested the utility of several HSP90 inhibitors, including PU-H71 (targeting GRP94), on a primary canine lung cancer line under HS/UPR stress compared to control conditions.

methodsWe cultured canine bronchoalveolar adenocarcinoma cells that showed high endogenous HSP90 and GRP94 expression; these levels substantially increased upon HS or UPR induction. We treated cells with HSP90 inhibitors 17-DMAG, 17-AAG or PU-H71 under standard conditions, HS or UPR. Cell viability/survival was assayed. Antibody arrays measured intracellular signalling and apoptosis profiles.

resultsHS and UPR had varying effects on cells treated with different HSP90 inhibitors; in particular, HS and UPR promoted resistance to inhibitors in short-term assays, but combinations of UPR stress and PU-H571 showed potent cytotoxic activity in longer-term assays. Array data indicated altered signalling pathways, with apoptotic and pro-survival implications. UPR induction + dual targeting of HSP90 and GRP94 swayed the balance toward apoptosis.

conclusionCellular stresses, endemic to tumors, or interventionally inducible, can deflect or enhance chemo-efficacy, particularly with chaperone-targeting drugs. Stress is likely not held accountable when testing new pharmacologics or assessing currently-used drugs. A better understanding of stress impacts on drug activities should be critical in improving therapeutic targeting and in discerning mechanisms of drug resistance.

Indexed as

apoptosiscell stressheat shockheat shock protein 90 inhibitorUnfolded protein response

Identifiers

PMID27829290
PMCPMC5675827
OpenAlexW2554881197

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.